White matter hyperintensities predict amyloid increase in Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 12, 2012, Pages 2766-2773

  Grimmer, Timo ^a   Faust, Maximilian ^a   Auer, Florian ^a   Alexopoulos, Panagiotis ^a   Förstl, Hans ^a   Henriksen, Gjermund ^a   Perneczky, Robert ^a   Sorg, Christian ^a   Yousefi, Behrooz H ^a   Drzezga, Alexander ^a   Kurz, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; Pittsburgh compound B; Positron emission tomography; Prospective study; White matter hyperintensities

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMAGE QUALITY; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; VOXEL BASED MORPHOMETRY; WHITE MATTER;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; BRAIN MAPPING; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES;

EID: 84866744392     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.01.016     Document Type: Article

References (34)

1. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259. 10.1007/BF00308809.
2. Brickman A.M., Honig L.S., Scarmeas N., Tatarina O., Sanders L., Albert M.S., Brandt J., Blacker D., Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch. Neurol 2008, 65:1202-1208. 10.1001/archneur.65.9.1202.
3. Carare R.O., Bernardes-Silva M., Newman T.A., Page A.M., Nicoll J.A., Perry V.H., Weller R.O. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol 2008, 34:131-144. 10.1111/j.1365-2990.2007.00926.x.
4. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., Goate A.M., Bales K.R., Paul S.M., Bateman R.J., Holtzman D.M. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med 2011, 3. 89ra57.
5. de Leeuw F.E., Richard F., de Groot J.C., van Duijn C.M., Hofman A., Van Gijn J., Breteler M.M. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004, 35:1057-1060. 10.1161/01.STR.0000125859.71051.83.
6. Drzezga A., Grimmer T., Henriksen G., Mühlau M., Perneczky R., Miederer I., Praus C., Sorg C., Wohlschläger A., Riemenschneider M., Wester H.J., Foerstl H., Schwaiger M., Kurz A. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009, 72:1487-1494. 10.1212/WNL.0b013e3181a2e8d0.
7. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118:5-36. 10.1007/s00401-009-0532-1.
8. Folstein M.F., Folstein S.E., McHugh P.R. "Mini Mental State". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6.
9. Friston K.J., Holmes A.P., Worsley K.J. Statistical parametric mapping in functional imaging: a general linear approach. Hum. Brain Mapp 1994, 2:189-210. 10.1002/hbm.460020402.
10. Grimmer T., Henriksen G., Wester H.J., Forstl H., Klunk W.E., Mathis C.A., Kurz A., Drzezga A. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol. Aging 2009, 30:1902-1909. 10.1016/j.neurobiolaging.2008.01.016.
11. Grimmer T., Riemenschneider M., Forstl H., Henriksen G., Klunk W.E., Mathis C.A., Shiga T., Wester H.J., Kurz A., Drzezga A. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 2009, 65:927-934. 10.1016/j.biopsych.2009.01.027.
12. Grimmer T., Tholen S., Yousefi B.H., Alexopoulos P., Förschler A., Förstl H., Henriksen G., Klunk W.E., Mathis C.A., Perneczky R., Sorg C., Kurz A., Drzezga A. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol. Psychiatry 2010, 68:879-884. 10.1016/j.biopsych.2010.05.013.
13. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356. 10.1126/science.1072994.
14. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., Coleman R.E. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med 2000, 41:1920-1928.
15. Hogh P., Garde E., Mortensen E.L., Jørgensen O.S., Krabbe K., Waldemar G. The apolipoprotein E epsilon4-allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities. Acta Neurol. Scand 2007, 115:248-253. 10.1111/j.1600-0404.2006.00779.x.
16. Huang Y.H., Zhang W.W., Lin L., Feng J., Zhao X.X., Guo W.H., Wei W. Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis?. Neuropathol. Appl. Neurobiol 2010, 36:237-247. 10.1111/j.1365-2990.2009.01049.x.
17. Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877. 10.1212/01.wnl.0000269790.05105.16.
18. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., Dekosky S.T., Fischman A.J., Greenberg S.M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol 2007, 62:229-234. 10.1002/ana.21164.
19. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774. 10.1126/science.1197623.
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
21. Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin. N. Am 2003, 13:769-780. 10.1016/S1052-5149(03)00099-6.
22. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., Mellits E.D., Clark C. Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD).
23. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010, 9:689-701. 10.1016/S1474-4422(10)70104-6.
24. Paternoster L., Chen W., Sudlow C.L. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke 2009, 40:2020-2026. 10.1161/STROKEAHA.108.542050.
25. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Koudstaal P.J., Oudkerk M., Hofman A., Breteler M.M. Cerebral white matter lesions and the risk of dementia. Arch. Neurol 2004, 61:1531-1534. 10.1001/archneur.61.10.1531.
26. Scheltens P., Barkhof F., Leys D., Pruvo J.P., Nauta J.J., Vermersch P., Steinling M., Valk J. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J. Neurol. Sci 1993, 114:7-12. 10.1016/0022-510X(93)90041-V.
27. Szentistvanyi I., Patlak C.S., Ellis R.A., Cserr H.F. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol 1984, 246:F835-F844.
28. Thal D.R. The pre-capillary segment of the blood-brain barrier and its relation to perivascular drainage in Alzheimer's disease and small vessel disease. TheScientificWorldJournal 2009, 9:557-563. 10.1100/tsw.2009.72.
29. Thal D.R., Rüb U., Orantes M., Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
30. Weller R.O. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J. Neuropathol. Exp. Neurol 1998, 57:885-894. 10.1097/00005072-199810000-00001.
31. Weller R.O., Subash M., Preston S.D., Mazanti I., Carare R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18:253-266.
32. Zhang E.T., Richards H.K., Kida S., Weller R.O. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol 1992, 83:233-239. 10.1007/BF00296784.
33. Ziolko S.K., Weissfeld L.A., Klunk W.E., Mathis C.A., Hoge J.A., Lopresti B.J., DeKosky S.T., Price J.C. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006, 33:94-102. 10.1016/j.neuroimage.2006.05.063.
34. Zivelin A., Rosenberg N., Peretz H., Amit Y., Kornbrot N., Seligsohn U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin. Chem 1997, 43:1657-1659.